Therapeutic Approach to Treatment
Introduction
This lecture outlines principles of therapy in veterinary cardiology, with a focus on the treatment of cardiovascular diseases in animals. The lecture emphasizes broad concepts related to the management of cardiac diseases, referencing specific therapeutic approaches and drug classes.
Overview of Today’s Topics
Principles of therapy in veterinary cardiology.
Focus on the management of cardiovascular diseases in young animals with murmurs.
Discussion of drug classes used in the treatment of cardiovascular diseases.
Importance of evidence-based medicine in guiding treatment decisions.
Animal Species Consideration
Companion Animals: Most evidence regarding cardiovascular therapies stems from studies conducted on dogs and cats.
Other Species: Some information exists concerning cardiac disease treatments in horses and exotic small animals.
Evidence Basis: Most solid evidence in veterinary literature relies heavily on data from companion animal studies.
Diagnosing and Staging Cardiac Disease
Diagnosis Process
Correct identification of the disease process is critical for effective treatment.
Involves a thorough diagnostic approach to accurately determine the type of cardiac disease in patients.
Staging the Disease
Utilize established staging systems for managing diseases, primarily the ACVIM (American College of Veterinary Internal Medicine) staging systems for dogs and cats.
Various systems exist such as:
New York Heart Association (used in humans)
Former systems like International Small Animal Cardiac Health Council and American College of Cardiology (less common now).
Evidence-Based Medicine
Definition: This approach involves deciding on treatment based on the highest level of available evidence for different patient disease stages.
Clinical Evidence Levels:
Randomized clinical trials (the highest level).
Retrospective cohort studies and case-controlled studies (lower levels).
Expert opinion (lowest level of evidence).
The Role of Clinical Trials
Clinical trials matter as they provide evidence crucial for effective treatments but often only address single questions.
Example: Kaplan-Meier Curve from the QUEST study evaluates outcomes of dogs receiving pimobendan vs. benazepril, illustrating survival rates and effectiveness of treatment.
Treatment Classes for Cardiovascular Issues
Key Classes of Drugs
Drugs acting on various aspects of the cardiovascular system can be divided based on their influence on physiologic parameters:
Afterload: Resistance against which the heart pumps.
Preload: Volume in the ventricles at the end of diastole.
Inotropy: Force of heart contractions.
Lusitropy: Relaxation of the heart muscle.
Chronotropy: Heart rate modulation.
Drug Class Examples
Diuretics:
Primary function is to reduce circulating fluid volume, targeting preload.
Major drugs: Furosemide (Lasix) targeting the ascending loop of Henle; thiazides, potassium-sparing diuretics such as spironolactone.
Considerations regarding side effects, electrolyte imbalances, and potential organ perfusion issues exist.
Vasodilators:
Facilitate easier ejection of blood from the heart and target afterload.
Include ACE inhibitors, such as enalapril, which promote arterial dilation and reduce blood pressure.
Drugs like nitroprusside are used in emergency settings.
Inotropes:
Improve contractility of the heart.
Examples: Digoxin, pimobendan, dobutamine.
Benefits and risks must be considered, especially for drugs linked to mortality.
Arrhythmia Management:
Antiarrhythmic drugs can be risky but necessary for symptomatic cases.
The risk of increased mortality complicates their use.
Diuretics: This Class in Depth
Mechanism of Action
Diuretics reduce fluid overload, relieving venous pressure in congestive heart failure (CHF).
Types of diuretics:
Loop Diuretics: Such as furosemide; act on loop of Henle, excellent diuretic effect.
Thiazide Diuretics: Less common, act in the distal convoluted tubule.
Potassium-Sparing Diuretics: Such as spironolactone, which prevent potassium loss while antagonizing aldosterone effects.
Administration and Monitoring
Dosage begins low in acute cases and may require escalation due to tolerance.
Monitor for dehydration and electrolyte imbalance as common side effects, and adjust as necessary.
Vasodilators
Mechanism
Vasodilators improve arterial blood flow and can indirectly reduce cardiac work.
Targeting systemic vascular resistance may lead to improved stroke volume and reduced myocardial oxygen demand.
Drug Examples
ACE Inhibitors:
Enalapril shows strong evidence for heart failure management.
Similar benefits in humans; limited evidence in cats.
Pimobendan:
Functions as both inotrope and vasodilator; shown to improve clinical outcomes in dogs.
Mechanism: Increases sensitivity of calcium in cardiac myofilaments without raising intracellular calcium levels.
Calcium Channel Blockers:
Amlodipine mainly provides antihypertensive effects.
Inotropic Drugs
Definition: Agents that increase the force of heart contractions.
Important considerations include the potential for negative impacts on long-term survival in heart failure patients (e.g., Milrinone in the PROMISE study).
Digoxin:
Offers symptom relief without adversely affecting mortality, effective in atrial fibrillation.
Pimobendan:
Well-studied with favorable outcomes in veterinary patients; used for various heart conditions.
Rhythm Management
Importance of accurately diagnosing rhythm disturbances for effective treatment.
Consider underlying conditions (e.g., electrolyte imbalances) that may be managed first.
If treatment is necessary, focus on control of the rhythm's rate and symptom management instead of restoring normal sinus rhythm.
Conclusion
The complexities of treating cardiac disease in veterinary patients require strong knowledge of various drug classes and a framework of evidence-based medicine.
Emphasis is placed on individual patient management and adjustments based on their unique clinical signs, underlying conditions, and response to therapy.